ArticleFrontiers in medicine2026
Rising burden of early-onset lung cancer among Chinese adolescents and young adults (1990-2023): a Bayesian age-period-cohort analysis with projections to 2038.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Early-onset lung cancer (diagnosed at age 15-39 years) remains uncommon, yet incidence is rising in several world regions. China-the largest contributor to global lung cancer mortality-has not had its youth burden comprehensively characterized or projected. Methods: Using the Global Burden of Disease Study 2023 (GBD 2023), we extracted annual incidence, prevalence, mortality, and disability-adjusted life-years (DALYs) for Chinese adolescents and young adults (AYA) aged 15-39 years from 1990 to 2023. Joinpoint regression quantified temporal slopes; age-period-cohort (APC) and Bayesian APC (BAPC) models dissected historical drivers. Two complementary forecasting frameworks, BAPC (structural) and autoregressive integrated moving average (ARIMA; time-series) were used to generate burden trajectories to 2038. Results: Between 1990 and approximately 2020, the age-standardized disease burden generally declined, followed by a recent increase through 2023. Males consistently exhibit a higher disease burden than females; the 35-39-year age band showed the heaviest burden. Age-period-cohort analysis revealed divergent cohort effects: Cohort rate ratios generally declined across successive birth cohorts, with lower risks observed among cohorts born after 1985. For both sexes combined, BAPC point projections indicated that ASIR would increase from 1.53 to 2.54 per 100,000 and the age-standardized DALY rate from 64.71 to 79.77 per 100,000 between 2023 and 2038. These endpoint predictions corresponded to Conclusion: After decades of decline, lung cancer burden in Chinese adolescents and young adults is creeping upward and may accelerate. Rising computed tomography screening intensity, persistent ambient pollution, evolving tobacco-product use, and hereditary susceptibility warrant urgent scrutiny. These findings inform precision prevention strategies-targeted tobacco control, cleaner-air policies, and risk-stratified early detection-to avert a foreseeable surge in early-onset lung cancer in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.